• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

How will retraining the TikTok algorithm impact users?

admin - Latest News - September 22, 2025
admin
38 views 25 secs 0 Comments



More details are coming out about the Trump administration’s new TikTok deal, including what will happen to the app’s famous and secretive algorithm and what that will mean for users’ experiences. The White House says President Donald Trump will sign the deal later this week.



Source link

TAGS:
PREVIOUS
Disney says 'Jimmy Kimmel Live' will return Tuesday
NEXT
Disney announces Jimmy Kimmel's late-night show will return to ABC airwaves
Related Post
September 27, 2025
Sept. 27, 2025, 5:30 AM EDTBy Berkeley Lovelace Jr.For people who rely on certain prescription drugs, including weight loss, asthma and cancer medications, President Donald Trump’s post announcing 100% tariffs on foreign brand-name drugs offers little clarity on when — or if — medications might see price hikes. “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump said on Truth Social late Thursday. “‘IS BUILDING’ will be defined as, ‘breaking ground’ and/or ‘under construction.’ There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”Experts say Trump’s post raises a lot of questions. Here are five major ones. What drugs will be impacted?Trump’s post doesn’t specify whether brand-name drugmakers with an existing U.S. plant would be exempt, whether that exemption would include all their products, or whether it would only be for the drugs manufactured at the U.S. site. Novo Nordisk and Eli Lilly, makers of the weight loss drugs Wegovy and Zepound, respectively, have announced plans to invest in U.S. manufacturing. But it’s unclear if their intent to invest will warrant an exemption. On Tuesday, Lilly announced plans for a $6.5 billion manufacturing facility in Houston that will produce Zepbound and its other GLP-1 drug, Mounjaro, following a recent commitment to build a $5 billion plant near Richmond, Virginia. Novo Nordisk, a Danish company, said in June it would spend $4.1 billion to construct a second GLP-1 fill-finish plant in Clayton, North Carolina.AstraZeneca, which makes the asthma drug Symbicort, also announced in July that it will invest $50 billion over the next five years to expand its research and development and manufacturing footprint in the U.S. Many other popular brand-name drugs, however, are primarily manufactured overseas, particularly in Europe, said Rena Conti, an associate professor at Boston University’s Questrom School of Business.Botox, made by Allergen, and the cancer drug Keytruda from drugmaker Merck are made in Ireland. (Keytruda’s manufacturing has increasingly moved to the United States in recent years, but it’s not clear if that would earn an exemption from Trump’s tariffs.)Others, including some for blood and lung cancers, as well as vaccines, are made in places like India and China, Conti said. “I think what’s most at risk here are branded products that come from China and India,” she said. The E.U. and Japan already have trade agreements in place that cover pharmaceuticals, she added, and it’s unclear whether the new tariff will supersede that. Will patients see prices increase?Only 1 in 10 of the prescriptions filled in the U.S. are for brand-name drugs; the vast majority are for generics, which are much cheaper and will not be affected by these tariffs. Whether patients see price increases will depend on how many drugmakers receive exemptions — and on whether companies choose to pass those costs on to patients at the pharmacy counter, said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School. ​​“Ultimately, tariffs are taxes on patients,” Kesselheim said, “and to the extent that drug companies see increases in cost due to tariffs, they will pass those costs on to patients.”Some companies may decide not to pass the costs along. So far, the 15% tariffs on imports from the E.U. haven’t translated into big price hikes for U.S. patients, Conti noted. To be sure, a 100% tariff would be far more costly for a company. Price hikes may not start right away, as drugmakers find out whether they qualify for an exemption. There also might be a lag since U.S. law prevents drugmakers from increasing the price of drugs faster than inflation.“What if you’re doing updates to the plant you currently have? What if you’re planning a facility? Do those count?” Kesselheim said. “It’s all very ambiguous.”Some patients may not notice additional price hikes at all, given how costly brand-name drugs already are in the U.S., said Arthur Caplan, the head of the Division of Medical Ethics at NYU Langone Medical Center in New York City. “I can certainly predict that some patients will immediately feel price increases that will shock them on some of these drugs,” Caplan said.Could insurers absorb the costs?Insurers and middlemen, known as pharmacy benefit managers, could try to negotiate drugmakers or absorb some of the tariff-related costs, Caplan said.It’s more likely, however, that they’d pass it on to patients in the short term, potentially in the form of a larger copay, he said.It’s not only patients with private insurance that should be worried about price hikes, Kesselheim said. Those who get their drugs covered through government health programs could also see price increases.“The government is the largest purchaser of prescription drugs in the market, through Medicare, Medicaid and the VA, so it’s really the government or government payers that are going to see the largest impact on price increases,” he said. Will tariffs spur more U.S. drug manufacturing?It’s unlikely, Kesselheim said. The decision to build a plant “is a complicated and expensive one” that requires several regulatory hurdles and years of planning.Conti noted that by the time new manufacturing plants are completed, Trump would likely be out of office.“It is somewhere between two years and five years to get new production facilities built,” she said, “and it can be in the millions of dollars depending on whether the product that you’re making is a small molecule drug or a biologic.”Even putting money back into an existing plant isn’t quick.“If you want to switch a line or retool a factory to make a product, then we’re talking about somewhere between 18 to 36 months to do that,” Conti said, “because you have to show the U.S. regulator that you can make it at this factory at scale, and the product is what it says it is, or is high quality and meets the quality standards of the U.S.”In a statement, Alex Schriver, a spokesperson for the trade group the Pharmaceutical Research and Manufacturers of America, said “most innovative medicines prescribed in America are already made in America” and companies continue to invest in the U.S.“Tariffs risk those plans because every dollar spent on tariffs is a dollar that cannot be invested in American manufacturing or the development of future treatments and cures,” Schriver said. “Medicines have historically been exempt from tariffs because they raise costs and could lead to shortages.”What about shortages?If Trump keeps his focus solely on brand-name drugs, U.S. patients are unlikely to face shortages, Kesselheim said.“Their profits are just so, so far beyond this tariff cost that they could probably be OK or raise the prices of the drugs,” he said. “They would probably not stop production as a result.”But that excludes, he added, some smaller companies who may make niche brand-name products and may not have the resources to take on the extra costs. If tariffs extend to generics, the risk is far greater, Caplan added. Unlike brand-name drugs, generic drugs are typically sold at close to the cost they’re made, he said, which makes it difficult for companies to justify the cost of building a new facility. They’d likely be forced to walk away from production or close their plants altogether.Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
October 24, 2025
SNAP recipients told to buy shelf-stable food or go to food banks as funding deadline looms
November 25, 2025
Ethiopian volcano records first eruption in 12 millennia
September 24, 2025
Sept. 24, 2025, 3:47 PM EDTBy Tyler KingkadeAfter dozens of school districts and colleges fired employees or placed them on leave over social media posts about Charlie Kirk’s assassination, some of those employees are turning to federal courts to get their jobs back. A former Ball State University staff member is suing the Indiana school’s president after she was fired for posting on Facebook: “Charlie Kirk’s death is a reflection of the violence, fear and hatred he sowed. It does not excuse his death, AND it’s a sad truth.”An art teacher in central Iowa filed a suit last week after the Oskaloosa school board voted to fire him for posting “1 Nazi down” about Kirk’s assassination.An elementary school teacher assistant is suing her Spartanburg County, South Carolina, district over what her lawsuit calls an unconstitutional social media policy. According to the suit, she was fired for posting a quote from Kirk in which he said it’s worth having “some gun deaths every single year” to protect the Second Amendment, and then adding the phrase “thoughts and prayers.” And on Wednesday, an art professor will plead his case before a federal judge in Sioux Falls, hoping to stop the University of South Dakota from firing him for posting on Facebook: “Where was all this concern when the politicians in Minnesota were shot? And the school shootings? And capital police? I have no thoughts or prayers for this hate spreading nazi. A shrug, maybe.”The schools have not yet responded in court. The universities and two districts declined to comment on pending litigation.The lawsuits are among the first actions educators have taken to combat a campaign propelled by conservative influencers and Republican lawmakers who urged schools and other employers to fire people who they say made light of or celebrated Kirk’s death. Those pushing for the firings have argued that teachers and professors with abhorrent views shouldn’t be allowed to influence students. Liberal-leaning critics have accused conservatives of embracing so-called cancel culture, which they had long condemned. Death of Charlie Kirk raises questions about future of free speech in America02:00Civil liberties groups have warned that some of the firings could violate the First Amendment, regardless of whether they simply criticize Kirk or openly celebrate his death. The legal challenges filed over the past two weeks will be important test cases on whether public employees can post statements deemed offensive, said Adam Goldstein, vice president of strategic initiatives at the Foundation for Individual Rights and Expression.“It’s an unfortunate necessity that the courts will have to weigh in here,” Goldstein said. “There’s no option here other than a number of cases where courts hopefully reinstruct us on how the First Amendment is supposed to work.”In the days after Kirk was shot earlier this month, Vice President JD Vance and other top Republicans urged citizens to report people who mock Kirk’s assassination to their employers. Secretary of Education Linda McMahon told Fox News last week that she’d “like to see more” college faculty who celebrate Kirk’s death fired or suspended.Some Democrats have shared similar sentiments. In Iowa, a leading Democratic gubernatorial candidate echoed calls to remove the Oskaloosa teacher. “I’d be pretty uncomfortable with my kids having teachers that celebrated someone’s murder,” Rob Sand, the candidate and current state auditor, told the Des Moines Register this week. Because the cases involve public employees, the employers have a higher bar to meet before firing them for speaking out, legal experts say. They will have to show the staff members’ posts created a disruption that interfered with classes, for instance, or the operation of a school. Goldstein said generating controversy or complaints is typically not enough to warrant a firing. Michael Hook, the University of South Dakota art professor, deleted his remarks after a few hours, and shared an apology that stated he regretted the original post. Through his lawyer, Hook declined to be interviewed.Hook filed a motion Tuesday to get an emergency order to block the university from moving forward with the next step in his termination process. He alleges his firing stems from angering “the wrong people,” noting that the governor and speaker of the state house had called for his termination. “When I read this post, I was shaking mad,” Gov. Larry Rhoden, a Republican, posted on X.An online petition to reinstate Hook has over 8,000 signatures.In many cases, Goldstein said, the teachers’ punishment seems disproportionate to their alleged offense, noting that an inappropriate post could be flagged without termination.“It’s very weird to live in a world where Charlie’s wife can forgive the shooter,” Goldstein said, “but we can’t forgive a teacher who quoted him.”Tyler KingkadeTyler Kingkade is a national reporter for NBC News, based in Los Angeles.
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved